ArticleEuropean urology open science2025
Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.Lasers in medical science · 2026Pooled it
- Validation of BIAS and IBCG criteria for predicting high-grade recurrence in low-grade NMIBC eligible for active surveillance.International urology and nephrology · 2026Article
- [Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare].Urologie (Heidelberg, Germany) · 2026Review
- Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.BMC cancer · 2026Article
- Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Bladder Cancer Group (IBCG) scoring system has been proposed for identifying patients suitable for active surveillance (AS) within the intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) population. Given that early recurrence has been associated with higher progression rates, we aimed to assess whether better integration of recurrence-free survival (RFS) into the IBCG risk stratification may further improve AS eligibility criteria. We retrospectively identified 241 recurrent IR-NMIBC patients (during the period 2013-2022) who were eligible for AS at the time of the first transurethral resection of a bladder tumor. Kaplan-Meier and multivariable Cox regression analyses evaluated the impact of IBCG risk factors and recurrence timing in predicting high-grade (HG) progression-free survival (PFS), while discrimination was assessed using Harrell's concordance index (C-index). Patients who recurred within 6 mo had significantly worse PFS than those with recurrence at >12 mo from diagnosis (3-yr PFS: 42% vs 74%, Patient summary: In this study, we looked at patients with bladder cancer who might be monitored (active surveillance) without immediate treatment. We found that if the cancer comes back within 6 mo, there is a higher chance that it will become more aggressive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.